Overview
Outsourcing-Pharma, a daily news service that provides news stories and data on pharmaceutical contract services, quoted Jack Hayes in an article titled “Can Nuclear Deal Make Iran a Contract Manufacturing Destination?” The article, published August 19, discusses the likelihood that US companies will consider Iran as a venue for pharmaceutical contract manufacturing.
According to the article, the current nuclear agreement by the US with Iran doesn’t include any commitment to remove sanctions that may restrict direct manufacturing activities.
When asked about pharmaceutical contract manufacturing agreements, Mr. Hayes says, “That would undoubtedly require transfer of technology and know-how, and US companies won’t be able to transfer their production technologies to Iran or provide service relating to developing technology in Iran without obtaining a specific license from the Office of Foreign Assets Controls (OFAC) – those restrictions would remain.”
The full article can be read at Outsourcing-Pharma.
